Reduction-Responsive Polymeric Micelles and Vesicles for Triggered Intracellular Drug Release

Abstract

Significance: The therapeutic effects of current micellar and vesicular drug formulations are restricted by slow and inefficient drug release at the pathological site. The development of smart polymeric nanocarriers that release drugs upon arriving at the target site has received a tremendous amount of attention for cancer therapy. Recent Advances: Taking advantage of a high reducing potential in the tumor tissues and in particular inside the tumor cells, various reduction-sensitive polymeric micelles and vesicles have been designed and explored for triggered anticancer drug release. These reduction-responsive nanosystems have demonstrated several unique features, such as good stability under physiological conditions, fast response to intracellular reducing environment, triggering drug release right in the cytosol and cell nucleus, and significantly improved antitumor activity, compared to traditional reduction-insensitive counterparts. Critical Issues: Although reductionsensitive micelles and polymersomes have accomplished rapid intracellular drug release and enhanced in vitro antitumor effect, their fate inside the cells including the mechanism, site, and rate of reduction reaction remains unclear. Moreover, the systemic fate and performance of reduction-sensitive polymeric drug formulations have to be investigated. Future Directions: Biophysical studies should be carried out to gain insight into the degradation and drug release behaviors of reduction-responsive nanocarriers inside the tumor cells. Furthermore, novel ligand-decorated reduction-sensitive nanoparticulate drug formulations should be designed and explored for targeted cancer therapy in vivo. Antioxid. Redox Signal. 21, 755-767.

Low-density lipoprotein-coupled micelles with reduction and pH dual sensitivity for intelligent co-delivery of paclitaxel and siRNA to breast tumor

“…44 About 0.5 mL volume of the acetone solution of pyrene (1 µM) was collected in a test tube, and the solvent was volatilized in nitrogen atmosphere. Then, 5 mL of the block copolymer solution at different concentrations was added.…”

Methemoglobin as a redox-responsive nanocarrier to trigger the in situ anticancer ability of artemisinin

“…Using bio-inspiration from the antimalarial mechanism of ART in nature, here we explored methemoglobin (MHb)-an oxidized form of hemoglobin with iron in the ferric state (Fe 3+ ) rather than in the ferrous state (Fe 2+ )-as a smart nanocarrier for hydrophobic ART. While MHb reacts very slowly with ART, 14,15 the upregulated reducing capacity [16][17][18][19] of the tumor tissue can work as an excellent biogenic trigger to reduce ferric iron in MHb to the ferrous state, activating its ability to generate free radicals and resulting in the cytotoxicity of ART in situ (Scheme 1).…”

Binary-copolymer system base on low-density lipoprotein-coupled N-succinyl chitosan lipoic acid micelles for co-delivery MDR1 siRNA and paclitaxel, enhances antitumor effects via reducing drug

“…Drug release from PTX-LDL-NSC-LA micelle was determined by dialysis method. 32 PTX-LDL-NSC-LA micelle solution (2 mL) was placed into a dialysis bag (8-14 k MWCO) sealed at both ends with clips. The dialysis bag was then placed into a jar containing 50 mL of the medium and stirred at 37 6 0.58C.…”